MS Type, Anti-CD20 Therapies Tied to Higher COVID-19 Mortality Risk

MS Type, Anti-CD20 Therapies Tied to Higher COVID-19 Mortality Risk

316112

MS Type, Anti-CD20 Therapies Tied to Higher COVID-19 Mortality Risk

A new meta-analysis revealed that, among multiple sclerosis (MS) patients, age, disease type, co-existing conditions, and the use of anti-CD20 therapies — such as ocrelizumab and rituximab — were associated with an increased risk of death from COVID-19. Overall, available data have suggested that people with MS have a 24% higher mortality risk from COVID-19 than the general population, for whom older age and comorbidities (other diseases) are also risk factors, the researchers noted. “We…

You must be logged in to read/download the full post.